Close
Novotech
Jabsco PureFlo 21 Single Use
Production & Manufacturing

Mylan Labs to buy SMS Indian manufacturing unit

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Drug Research

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
Drug Research

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
Knowledge Bank

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.
- Advertisement -

Mylan Laboratories has agreed to purchase SMS Pharmaceuticals’ manufacturing unit-VI in Visakhapatnam, Andhra Pradesh, India, for a total sum of INR1.73bn ($33m).

The manufacturing unit was designed for the production of cancer medications and the active ingredients for cancer drugs.

SMS will use the proceeds to clear some of its existing debts, cut overhead costs, reports the Hindu Business Line.

In addition, SMS will use the finance to strengthen its existing production facilities and working capital.

SMS Pharma, which is involved in active pharmaceutical intermediaries manufacturing, said the legal process would take a couple of months.

 

Latest stories

Previous article
Biostar to manufacture, supply five additional drugs to Xijing Hospital
Next article
Fujifilm to manufacture bulk substance for ThromboGenics’ eye medication

Related stories

Drug Research

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
Drug Research

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
Knowledge Bank

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.
Business & Industry

AbbVie to Invest $1.4B in North Carolina Manufacturing Plant

AbbVie has outlined plans to build a major new...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
mobile field hospitals emergency healthcare

How Mobile Field Hospitals Are Changing Emergency Care

Husky SEM Plastik blood collection tubes

Husky and SEM Plastik Announce Strategic Collaboration to Advance Blood Collection...